| |||||||||
- Description
- Phenotype
- Genes & alleles
- Genotyping
- Health & husbandry
- References
- Purchasing information
- Terms of Use
Description
Strain Information
Former Names B6129-TgN(WapCre)11738Mam (Changed: 15-DEC-04 ) Type Mutant Strain; Transgenic; Additional information on Genetically Engineered Mutant Mice. Mating System +/+ sibling x Hemizygote (Female x Male) Species laboratory mouse Donating Investigator Lothar Hennighausen, National Institutes of Health Description
This transgenic strain expresses P1 Cre recombinase under the control of the Wap (whey acidic protein) promoter. In mammary gland tissues, the Wap promoter directs expression to secretory epithelium. A maximum of Cre mediated recombination is achieved during pregnancy and lactation, but recombined cells are still present after involution and complete remodeling of the gland. Cre recombinase expression is not entirely restricted to mammary gland, however. A limited amount of Cre activity has been reported in brain tissue.Development
A transgenic construct containing the Wap promoter, Cre recombinase and beta-globin intronic sequence for poly A addition was injected into fertilized oocytes. Founder lines were subsequently established. This strain was generated on a B6SJLF1/J background. It was bred to FVB mice before being crossed to B6129F1 mice by the donating investigator.
Control Information
| Control | ||
|---|---|---|
| Noncarrier | ||
| Considerations for Choosing Controls | ||
Related Strains
Strains carrying other alleles of Wap
002409 B6;SJL-Tg(Wap-HRAS)69Lln Chr YSJL/J 003189 C57BL/6J-Tg(WAPTAg)3Knw/J 002500 C57BL/6J-Tg(WapIgf1)39Dlr/J 003188 C57BL/6J-Tg(WapTAg)1Knw 002410 FVB.Cg-Tg(Wap-HRAS)69Lln Chr YSJL/J 003078 FVB.Cg-Tg(WapIgf1)39Dlr/J 002678 FVB.Cg-Tg(WapTgfa)215Bri/J 002755 FVB/N-Tg(WapNotch4)10Rnc/J View Strains carrying other alleles of Wap (8 strains)
Additional Web Information
Cre-lox Systems
Genetic Quality Control Annual Report
Phenotype
Phenotype Information
This mouse can be used to support research in many areas including:
cre relatedCancer Research
Other
Research Tools
Cancer Research
Cre-lox System (Cre Recombinase Expression)
Genetics Research (Mutagenesis and Transgenesis: Cre-lox System)
Genetics Research (Tissue/Cell Markers: Cre-lox System)
Reproductive Biology Research (Cre-lox System)
Research Tools
Cre-lox System
Genetics Research (Mutagenesis and Transgenesis: Cre-lox System)
Genes & Alleles
Gene & Allele Information
| Allele Symbol | Tg(Wap-cre)11738Mam | ||
|---|---|---|---|
| Allele Name | transgene insertion 11738, Lothar Hennighausen | ||
| Allele Type | Transgenic (Cre/Flp) | ||
| Common Name(s) | WAP-Cre; WC; | ||
| Mutation Made By | Kay-Uwe Wagner, University of Nebraska Medical Center | ||
| Strain of Origin | (C57BL/6 x SJL)F1 | ||
| Site of Expression | mammary gland tissues, specifically the secretory epithelium; not entirely restricted to mammary gland, a limited amount of cre activity has been reported in brain tissue | ||
| Expressed Gene | cre, cre recombinase, bacteriophage P1 | ||
| Cre recombinase is an enzyme derived from the bacteriophage P1 that specifically recognizes loxP sites. Cre has been shown to effectively mediate the excision of DNA located between loxP sites. After the excision event, the DNA ends recombine leaving a single loxP site in place of the intervening sequence. | |||
| Promoter | Wap, whey acidic protein, mouse, laboratory | ||
| Molecular Note | This transgene directs the expression of Cre recombinase under the control of a 2.6 kb (EcoRI-Asp718) mouse whey acidic protein (Wap) promoter fragment. The Wap promoter directed expression of Cre recombinase in the mammary glands of late pregnant and lactating female mice. No expression was detected in mammary tissue of virgin mice. [MGI Ref ID J:67925] | ||
Genotyping
Genotyping Information
Genotyping Protocols
Tg(Wap-cre)11738Mam, STD PCR, vers. 1
Helpful Links
Optimizing PCR Protocols
References
References
Selected Reference(s)
Wagner KU; Wall RJ; St-Onge L; Gruss P; Wynshaw-Boris A; Garrett L; Li M; Furth PA; Hennighausen L. 1997. Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res 25(21):4323-30. [PubMed: 9336464] [MGI Ref ID J:67925]
Additional References
McPherson JP; Lemmers B; Hirao A; Hakem A; Abraham J; Migon E; Matysiak-Zablocki E; Tamblyn L; Sanchez-Sweatman O; Khokha R; Squire J; Hande MP; Mak TW; Hakem R. 2004. Collaboration of Brca1 and Chk2 in tumorigenesis. Genes Dev 18(10):1144-53. [PubMed: 15131084] [MGI Ref ID J:90512]
Wagner KU; Boulanger CA; Henry MD; Sgagias M; Hennighausen L; Smith GH. 2002. An adjunct mammary epithelial cell population in parous females: its role in functional adaptation and tissue renewal. Development 129(6):1377-86. [PubMed: 11880347] [MGI Ref ID J:75045]
Wagner KU; Krempler A; Qi Y; Park K; Henry MD; Triplett AA; Riedlinger G; Rucker III EB; Hennighausen L. 2003. Tsg101 is essential for cell growth, proliferation, and cell survival of embryonic and adult tissues. Mol Cell Biol 23(1):150-62. [PubMed: 12482969] [MGI Ref ID J:80891]
Tg(Wap-cre)11738Mam relatedAhmed F; Wyckoff J; Lin EY; Wang W; Wang Y; Hennighausen L; Miyazaki J; Jones J; Pollard JW; Condeelis JS; Segall JE. 2002. GFP Expression in the Mammary Gland for Imaging of Mammary Tumor Cells in Transgenic Mice. Cancer Res 62(24):7166-9. [PubMed: 12499251] [MGI Ref ID J:80828]
Bierie B; Stover DG; Abel TW; Chytil A; Gorska AE; Aakre M; Forrester E; Yang L; Wagner KU; Moses HL. 2008. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res 68(6):1809-19. [PubMed: 18339861] [MGI Ref ID J:133311]
Brodie SG; Xu X; Qiao W; Li WM; Cao L; Deng CX. 2001. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene 20(51):7514-23. [PubMed: 11709723] [MGI Ref ID J:72815]
Bry C; Maass K; Miyoshi K; Willecke K; Ott T; Robinson GW; Hennighausen L. 2004. Loss of connexin 26 in mammary epithelium during early but not during late pregnancy results in unscheduled apoptosis and impaired development. Dev Biol 267(2):418-29. [PubMed: 15013803] [MGI Ref ID J:88743]
Carstens MJ; Krempler A; Triplett AA; Van Lohuizen M; Wagner KU. 2004. Cell cycle arrest and cell death are controlled by p53-dependent and p53-independent mechanisms in Tsg101-deficient cells. J Biol Chem 279(34):35984-94. [PubMed: 15210712] [MGI Ref ID J:92528]
Chang MY; Boulden J; Sutanto-Ward E; Duhadaway JB; Soler AP; Muller AJ; Prendergast GC. 2007. Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Res 67(1):100-7. [PubMed: 17210688] [MGI Ref ID J:117330]
Cheung AM; Elia A; Tsao MS; Done S; Wagner KU; Hennighausen L; Hakem R; Mak TW. 2004. Brca2 deficiency does not impair mammary epithelium development but promotes mammary adenocarcinoma formation in p53(+/-) mutant mice. Cancer Res 64(6):1959-65. [PubMed: 15026330] [MGI Ref ID J:89150]
Cui Y; Miyoshi K; Claudio E; Siebenlist UK; Gonzalez FJ; Flaws J; Wagner KU; Hennighausen L. 2002. Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem 277(20):17830-5. [PubMed: 11884400] [MGI Ref ID J:76553]
Cui Y; Riedlinger G; Miyoshi K; Tang W; Li C; Deng CX; Robinson GW; Hennighausen L. 2004. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol 24(18):8037-47. [PubMed: 15340066] [MGI Ref ID J:92770]
Declercq J; Skaland I; Van Dyck F; Janssen EA; Baak JP; Drijkoningen M; Van de Ven WJ. 2008. Adenomyoepitheliomatous lesions of the mammary glands in transgenic mice with targeted PLAG1 overexpression. Int J Cancer 123(7):1593-600. [PubMed: 18649356] [MGI Ref ID J:140057]
Deng CX; Xu X. 2004. Generation and analysis of brca1 conditional knockout mice. Methods Mol Biol 280:185-200. [PubMed: 15187254] [MGI Ref ID J:90788]
Feng Y; Manka D; Wagner KU; Khan SA. 2007. Estrogen receptor-{alpha} expression in the mammary epithelium is required for ductal and alveolar morphogenesis in mice. Proc Natl Acad Sci U S A 104(37):14718-23. [PubMed: 17785410] [MGI Ref ID J:124962]
Frau E; Magnon C; Opolon P; Connault E; Opolon D; Beermann F; Abitbol M; Perricaudet M; Bouquet C. 2007. A gene transfer comparative study of HSA-conjugated antiangiogenic factors in a transgenic mouse model of metastatic ocular cancer. Cancer Gene Ther 14(3):251-61. [PubMed: 17082795] [MGI Ref ID J:133447]
Humphreys RC; Bierie B; Zhao L; Raz R; Levy D; Hennighausen L. 2002. Deletion of Stat3 blocks mammary gland involution and extends functional competence of the secretory epithelium in the absence of lactogenic stimuli. Endocrinology 143(9):3641-50. [PubMed: 12193580] [MGI Ref ID J:81459]
Klein L; Khazaie K; von Boehmer H. 2003. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci U S A 100(15):8886-91. [PubMed: 12857946] [MGI Ref ID J:125750]
Kumaraswamy E; Carlson BA; Morgan F; Miyoshi K; Robinson GW; Su D; Wang S; Southon E; Tessarollo L; Lee BJ; Gladyshev VN; Hennighausen L; Hatfield DL. 2003. Selective removal of the selenocysteine tRNA [Ser]Sec gene (Trsp) in mouse mammary epithelium. Mol Cell Biol 23(5):1477-88. [PubMed: 12588969] [MGI Ref ID J:82321]
Lam MH; Liu Q; Elledge SJ; Rosen JM. 2004. Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 6(1):45-59. [PubMed: 15261141] [MGI Ref ID J:91266]
Le Provost F; Riedlinger G; Hee Yim S; Benedict J; Gonzalez FJ; Flaws J; Hennighausen L. 2002. The aryl hydrocarbon receptor (AhR) and its nuclear translocator (Arnt) are dispensable for normal mammary gland development but are required for fertility. Genesis 32(3):231-9. [PubMed: 11892012] [MGI Ref ID J:76280]
Li W; Qiao W; Chen L; Xu X; Yang X; Li D; Li C; Brodie SG; Meguid MM; Hennighausen L; Deng CX. 2003. Squamous cell carcinoma and mammary abscess formation through squamous metaplasia in Smad4/Dpc4 conditional knockout mice. Development 130(24):6143-53. [PubMed: 14597578] [MGI Ref ID J:86484]
Li W; Xiao C; Vonderhaar BK; Deng CX. 2007. A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation. Oncogene 26(51):7204-12. [PubMed: 17496925] [MGI Ref ID J:129624]
Li Z; Tognon CE; Godinho FJ; Yasaitis L; Hock H; Herschkowitz JI; Lannon CL; Cho E; Kim SJ; Bronson RT; Perou CM; Sorensen PH; Orkin SH. 2007. ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. Cancer Cell 12(6):542-58. [PubMed: 18068631] [MGI Ref ID J:130323]
Loladze AV; Stull MA; Rowzee AM; Demarco J; Lantry JH rd; Rosen CJ; Leroith D; Wagner KU; Hennighausen L; Wood TL. 2006. Epithelial-specific and stage-specific functions of insulin-like growth factor-I during postnatal mammary development. Endocrinology 147(11):5412-23. [PubMed: 16901968] [MGI Ref ID J:117180]
Long W; Wagner KU; Lloyd KC; Binart N; Shillingford JM; Hennighausen L; Jones FE. 2003. Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5. Development 130(21):5257-68. [PubMed: 12954715] [MGI Ref ID J:86319]
Manuylov NL; Smagulova FO; Tevosian SG. 2007. Fog2 excision in mice leads to premature mammary gland involution and reduced Esr1 gene expression Oncogene 26(36):5204-13. [PubMed: 17310981] [MGI Ref ID J:120985]
McPherson JP; Lemmers B; Hirao A; Hakem A; Abraham J; Migon E; Matysiak-Zablocki E; Tamblyn L; Sanchez-Sweatman O; Khokha R; Squire J; Hande MP; Mak TW; Hakem R. 2004. Collaboration of Brca1 and Chk2 in tumorigenesis. Genes Dev 18(10):1144-53. [PubMed: 15131084] [MGI Ref ID J:90512]
Miyoshi K; Shillingford JM; Le Provost F; Gounari F; Bronson R; von Boehmer H; Taketo MM; Cardiff RD; Hennighausen L; Khazaie K. 2002. Activation of beta -catenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias. Proc Natl Acad Sci U S A 99(1):219-24. [PubMed: 11773619] [MGI Ref ID J:73556]
Morroni M; Giordano A; Zingaretti MC; Boiani R; De Matteis R; Kahn BB; Nisoli E; Tonello C; Pisoschi C; Luchetti MM; Marelli M; Cinti S. 2004. Reversible transdifferentiation of secretory epithelial cells into adipocytes in the mammary gland. Proc Natl Acad Sci U S A 101(48):16801-6. [PubMed: 15556998] [MGI Ref ID J:94729]
Nemade RV; Bierie B; Nozawa M; Bry C; Smith GH; Vasioukhin V; Fuchs E; Hennighausen L. 2004. Biogenesis and function of mouse mammary epithelium depends on the presence of functional alpha-catenin. Mech Dev 121(1):91-9. [PubMed: 14706703] [MGI Ref ID J:87469]
Oh KB; Stanton MJ; West WW; Todd GL; Wagner KU. 2007. Tsg101 is upregulated in a subset of invasive human breast cancers and its targeted overexpression in transgenic mice reveals weak oncogenic properties for mammary cancer initiation. Oncogene 26(40):5950-9. [PubMed: 17369844] [MGI Ref ID J:121475]
Robinson GW; Pacher-Zavisin M; Zhu BM; Yoshimura A; Hennighausen L. 2007. Socs 3 modulates the activity of the transcription factor Stat3 in mammary tissue and controls alveolar homeostasis. Dev Dyn 236(3):654-61. [PubMed: 17205581] [MGI Ref ID J:118349]
Semba S; Han SY; Qin HR; McCorkell KA; Iliopoulos D; Pekarsky Y; Druck T; Trapasso F; Croce CM; Huebner K. 2006. Biological functions of mammalian Nit1, the counterpart of the invertebrate NitFhit Rosetta stone protein, a possible tumor suppressor. J Biol Chem 281(38):28244-53. [PubMed: 16864578] [MGI Ref ID J:115052]
Shillingford JM; Miyoshi K; Robinson GW; Bierie B; Cao Y; Karin M; Hennighausen L. 2003. Proteotyping of mammary tissue from transgenic and gene knockout mice with immunohistochemical markers: a tool to define developmental lesions. J Histochem Cytochem 51(5):555-65. [PubMed: 12704203] [MGI Ref ID J:124525]
Thangaraju M; Rudelius M; Bierie B; Raffeld M; Sharan S; Hennighausen L; Huang AM; Sterneck E. 2005. C/EBPdelta is a crucial regulator of pro-apoptotic gene expression during mammary gland involution. Development 132(21):4675-85. [PubMed: 16192306] [MGI Ref ID J:102705]
Trimboli AJ; Fukino K; de Bruin A; Wei G; Shen L; Tanner SM; Creasap N; Rosol TJ; Robinson ML; Eng C; Ostrowski MC; Leone G. 2008. Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 68(3):937-45. [PubMed: 18245497] [MGI Ref ID J:131862]
Wagner KU; Boulanger CA; Henry MD; Sgagias M; Hennighausen L; Smith GH. 2002. An adjunct mammary epithelial cell population in parous females: its role in functional adaptation and tissue renewal. Development 129(6):1377-86. [PubMed: 11880347] [MGI Ref ID J:75045]
Wagner KU; Krempler A; Qi Y; Park K; Henry MD; Triplett AA; Riedlinger G; Rucker III EB; Hennighausen L. 2003. Tsg101 is essential for cell growth, proliferation, and cell survival of embryonic and adult tissues. Mol Cell Biol 23(1):150-62. [PubMed: 12482969] [MGI Ref ID J:80891]
Wagner KU; Krempler A; Triplett AA; Qi Y; George NM; Zhu J; Rui H. 2004. Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol Cell Biol 24(12):5510-20. [PubMed: 15169911] [MGI Ref ID J:90883]
Wang RH; Zheng Y; Kim HS; Xu X; Cao L; Luhasen T; Lee MH; Xiao C; Vassilopoulos A; Chen W; Gardner K; Man YG; Hung MC; Finkel T; Deng CX. 2008. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell 32(1):11-20. [PubMed: 18851829] [MGI Ref ID J:141108]
Weaver Z; Montagna C; Xu X; Howard T; Gadina M; Brodie SG; Deng CX; Ried T. 2002. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 21(33):5097-107. [PubMed: 12140760] [MGI Ref ID J:77948]
Wijnhoven SW; Zwart E; Speksnijder EN; Beems RB; Olive KP; Tuveson DA; Jonkers J; Schaap MM; van den Berg J; Jacks T; van Steeg H; de Vries A. 2005. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res 65(18):8166-73. [PubMed: 16166291] [MGI Ref ID J:101617]
Wyckoff JB; Wang Y; Lin EY; Li JF; Goswami S; Stanley ER; Segall JE; Pollard JW; Condeelis J. 2007. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 67(6):2649-56. [PubMed: 17363585] [MGI Ref ID J:120318]
Xu X; Wagner KU; Larson D; Weaver Z; Li C; Ried T; Hennighausen L ; Wynshaw-Boris A ; Deng CX. 1999. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation [see comments] Nat Genet 22(1):37-43. [PubMed: 10319859] [MGI Ref ID J:54533]
Zhang D; Hirota T; Marumoto T; Shimizu M; Kunitoku N; Sasayama T; Arima Y; Feng L; Suzuki M; Takeya M; Saya H. 2004. Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models. Oncogene 23(54):8720-30. [PubMed: 15480417] [MGI Ref ID J:94713]
Zhao L; Hart S; Cheng J; Melenhorst JJ; Bierie B; Ernst M; Stewart C; Schaper F; Heinrich PC; Ullrich A; Robinson GW; Hennighausen L. 2004. Mammary gland remodeling depends on gp130 signaling through Stat3 and MAPK. J Biol Chem 279(42):44093-100. [PubMed: 15292206] [MGI Ref ID J:93986]
Health & husbandry
Health & Colony Maintenance Information
Colony Maintenance
Mating System +/+ sibling x Hemizygote (Female x Male)
Purchasing information
Pricing, Supply Level & Notes, Controls, General Terms & Conditions
Pricing
| Pricing for USA, Canada and Mexico shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $1900.00 Cryopreserved Embryos Fee $1600.00
Additional Supply Details
| Pricing for International shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $2470.00 Cryopreserved Embryos Fee $2080.00
Additional Supply Details
|
|
|
Supply Details
| Standard Supply | Repository-Cryopreserved. Must Be Recovered. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
|
Control Information
| Control | ||
|---|---|---|
| Noncarrier | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
General Terms and Conditions
See Terms of Use
The Jackson Laboratory's Genotype Promise
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.Ordering and Purchasing Information
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form
Terms of Use
Terms of Use
General Terms and Conditions
Effective September 26, 2007: License Requirements for Strains using Cre-lox Technology only apply in Canada, see Licenses for Strains using Cre-lox Technology.
Contact information
General inquiries
Contracts Administration
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
JAX® Mice & Services Conditions of Use
“Each recipient institution, including its employees and other researchers under its control (RECIPIENT), of mice or services using mice from The Jackson Laboratory (TJL) agrees that such mice, descendants of those mice derived by inbreeding or crossbreeding, including unmodified derivatives of those mice or their descendants (“MICE”) shall not be: (i) used for any purpose other than the internal research of the RECIPIENT, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services with respect to MICE. Acceptance of MICE from TJL shall be deemed agreement by RECIPIENT to these conditions, and departure from these conditions requires The Jackson Laboratory’s prior written authorization.”No Warranty
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.
No Liability
In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.
MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.
Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.